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Abstract
Over the past decade, platelet-rich plasma (PRP) has been used in several fields 
of medicine to promote cell growth and expedite wound healing for the treatment 
of arthritis, nerve injury, tendinitis, bone regeneration, cardiac muscle repair, and 
oral & plastic surgery. Recently, researchers have been applying autologous PRP to 
bolster the growth of endometrial lining in patients with a history of endometrium-
related failed embryo transfers. Evidence reveals that PRP is a rich source of active 
cytokines and various growth factors, which come from an autologous source that 
can be easily attained from peripheral blood without risk of disease transmission 
to the patient. In this review, several studies were analyzed that involved patients 
18–42 years of age undergoing hormone replacement therapy (HRT) in preparation 
for embryo transfer and serial transvaginal ultrasound in conjunction with PRP 
infusions into the endometrium via an intrauterine insemination (IUI) catheter. 
Exclusion criteria included patients with endometritis, polyps, or adhesions. 
Embryo transfers (ET) were performed when the endometrial lining achieved a 
thickness of >7 mm. The database indicates that PRP infusion therapy is a promis-
ing low-cost treatment for HRT patients that significantly increases endometrial 
thickness and improves pregnancy success in a previous suboptimal ET patient 
population.
Keywords: cytokines, embryo transfer, endometrial lining, endometrium,  
growth factors, hormone replacement therapy, infusion, platelet-rich plasma, 
suboptimal lining
Key Points
Evidence shows that PRP infusion directly into the endometrium enhances lining development in 
patients suffering from chronically refractive or underdeveloped endometrium. Chemical pregnancy in 
patients that underwent PRP infusion with frozen embryo transfer was 50% (108/216) in comparison to 
17.1% (16/93) in patients that did not receive PRP treatment.
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1. Introduction
The overall objective of this review was to determine if platelet-rich plasma 
(PRP) infusions are viable alternatives to current treatments for thin endometrial 
lining, and to distinguish if PRP infusions increase endometrial thickness and 
implantation in patients that underwent treatment in eight different case studies.
Platelet-rich plasma is prepared from autologous whole blood collected from a 
patient’s peripheral vein, mixed with an acid citrate dextrose solution A (ACD-A) 
anticoagulant, and processed to separate platelets from remaining blood compo-
nents [1]. Platelet-rich plasma is recognized as plasma from autologous blood with 
4–5 times the concentration of normal platelet levels; these high concentrations of 
PRP contain cytokines and growth factors including: vascular endothelial growth 
factor (VEGF), transforming growth factor (TGF), platelet-derived growth factor 
(PDGF) and epidermal growth factor (EGF) [2, 3]. Because of the expression of 
several regenerative growth factors, PRP is being used in several fields of medicine 
to promote wound regeneration including: arthritis, nerve injury, tendinitis, bone 
regeneration, cardiac muscle repair, alopecia, and plastic and oral surgery recovery 
[4, 5]. When the body is injured, a natural healing process occurs that floods the 
wound site with activated platelets that instantly promote cell regeneration and 
proliferation. It is theorized that PRP may be used to promote the same growth 
and proliferation in endometrium that have previous suboptimal growth patterns. 
Similar research, such as endometrial scratching, has been studied to promote the 
generation of growth factors to increase implantation; however, the concentra-
tion of platelet levels within direct PRP infusion into the endometrium is vastly 
superior to the natural, localized endometrial healing process that occurs with the 
scratching method.
Other treatment strategies for thin endometrial lining have varied throughout 
recent years, but have been inclusive of extended use of exogenous estradiol, low-
dose aspirin, vitamin E supplementation, and use of granulocyte colony stimulation 
factor (G-CSF), but not all have been proven effective [6–9]. The minimal endo-
metrial thickness suggested for successful implantation at embryo transfer is 7 mm 
[10], however, there are those that argue endometrial lining is a poor indicator for 
pregnancy outcomes and therefore should not be heavily considered [11]. During 
typical HRT cycles, estradiol administration is regulated from day 2 or day 3 of an 
average 28 day cycle and continues until the endometrial lining reaches optimal 
thickness for transfer (typically >7 mm) at which time progesterone administration 
then occurs [12]. This model is utilized in IVF clinics globally; however, patients 
who fail to reach the recommended endometrial thickness often undergo canceled 
cycles in which they have wasted valuable time, medications, and expenses without 
receiving an embryo transfer.
Thin endometrial lining or suboptimal endometrial growth is a problem that 
affects up to 5% of the patients undergoing IVF treatment [13]. These patients often 
experience the emotionally and physically traumatizing effects of canceled cycles 
or repeated implantation failure (RIF). It is proven that growth factors expressed in 
the endometrium of women with RIF are less than those expressed in normal fertile 
women [14]. These growth factors can be stimulated by infusion of autologous PRP 
into the endometrium in conjunction with HRT prior to embryo transfer. However, 
many factors are involved in successful embryonic implantation, not limited to 
embryo quality, but also a synchrony between the embryo and the endometrium in 
addition to any immunological factors [15]. Without optimal endometrial growth, 
this synchrony becomes far less likely as the endometrium does not express the 
adequate genes nor growth factors involved in embryonic implantation [16, 17].
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2. PRP collection and infusion
Through multiple studies, PRP processing was performed similarly. On the 10th 
day of HRT, Chang and coworkers drew 15 ml of autologous blood into a tube with 
5 ml of Acid Citrate A Anticoagulant (ACD-A) and centrifuged; separating red 
blood cells, a gel buffy coat, and cellular plasma. The plasma and buffy coat were 
then transferred to a second tube and centrifuged again, yielding 0.5–1 ml of PRP 
[18]. Both Zadehmodarres and Nazari and their colleagues drew 17.5 ml of blood on 
day 9 or 10 of HRT into 2.5 ml of ACD-A and similarly centrifuged twice to obtain 
0.5 ml of PRP [19, 20]. Tandulwadkar et al. used 10 ml of autologous blood into 
an unspecified amount of ACD-A; which was centrifuged sequentially utilizing 
first a soft spin for 15 minutes, followed by a hard spin for 6 minutes, again yield-
ing between 0.5 and 0.8 ml of PRP [21]. Eftekhar and others used an alternative 
approach, collecting PRP on the 13th day of HRT by drawing 8.5 ml of peripheral 
venous blood into a syringe containing 1.5 ml of ACD-A that was then centrifuged 
for 10 minutes; following first centrifugation, the buffy coat and plasma layer 
were then removed and centrifuged again, yielding 1.5 ml of PRP [22]. Meanwhile, 
Hounyoung et al. collected 18 ml of venous blood in a 30 ml syringe prepared 
with 2 CC of ACD-A and then centrifuged twice to obtain 0.7–1.0 ml of PRP [23]. 
Nazari and coworkers performed a follow-up study utilizing a double-blinded 
trial in which 30 patients underwent PRP infusion, prepared in the same manner 
as the initial pilot study [19], and 30 patients underwent placebo PRP infusions 
[24]. Chang et al. performed a secondary study as well, involving a larger cohort 
of patients compared against a control group, and performed PRP collection as 
previously reported [18, 25]. All studies transfused the PRP into the endometrium 
using an IUI catheter, and then repeated intravaginal ultrasound 48 hours later to 
measure endometrial growth; patients who did not reach the desired lining thick-
ness (>7 mm deemed adequate in all studies) were then treated with a second round 
of PRP infusion [18–25].
2.1 Hormone replacement therapy
In the past, IVF clinics allowed for natural cycle frozen embryo transfer in 
which they permitted endometrial lining to develop on its own, but it resulted 
in many timing issues with need for frequent monitoring and cancelation due to 
anovulation and poor development of the endometrium. Today, most clinics have 
moved fully to HRT protocols that allow for artificial stimulation of the endome-
trium that can be easily tracked utilizing blood serum and ultrasound assessment 
to time an embryo transfer concordant with a receptive endometrium. In humans, 
estrogen stimulates endometrial growth and induces progesterone receptors as it 
moves naturally through the menstrual cycle. After ovulation, the endometrium 
is exposed to progesterone which induces morphological and biochemical changes 
that alter the endometrium from the proliferative phase to the secretory phase 
[17]. In HRT cycles, estradiol administration (typically Estradiol Valerate) occurs 
until the lining has reached a thickness of greater than 7 mm, at which time pro-
gesterone is then administered for the number of days proportional to the embryo 
being transferred (i.e., a day 6 blastocyst will receive progesterone for 6 days) and 
then the embryo is transferred to a supposedly receptive endometrium [26, 27]. In 
these HRT cycles, patients receive estradiol during the follicular phase that inhibits 
gonadotropin secretion and prevents follicular development and ovulation. The 
start of the luteal phase can be exactly pinpointed, as it starts when progesterone is 
added to estradiol dosages.
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2.2 Methodology
HRT allows for artificial stimulation of endometrial growth via hormone 
administration orally, transdermally, intramuscularly, vaginally, subcutane-
ously, or a combination of both. Most clinics administer estradiol for several 
days until the endometrial lining has reach a point of optimal growth, at which 
time they will then administer progesterone to induce the secretory phase of 
cycle that promotes embryo implantation [21]. Each of the studies examined in 
this review conducted HRT protocols concordant with physician recommenda-
tion as follows:
Chang et al.: In the pilot study, Estradiol Valerate (E2V) started at 3 mg/d on day 
3 of menses and increased every 4 days up to a max of 12 mg/d; and in the cohort 
study, E2V started at 6 mg/d and subsequently increased to 12 mg/d [18, 25]. The 
pilot study included five patients suffering from chronically non-responsive thin 
endometrium (5.9–6.6 mm) who underwent PRP infusion on the 10th day of HRT 
and lining was measured via transvaginal ultrasound. In the cohort study, platelet-
rich plasma infusion was also performed on the 10th day of HRT, and endometrial 
thickness was measured in both the control group and study group.
Zadehmodarres et al.: Estradiol Valerate started at 6 mg/d on day 3 of menses, 
and increased to 8–9 mg/d. Suppository progesterone was started when endometrial 
thickness reached >7 mm and continued for 2 weeks after ET [19]. PRP infusion was 
administered on the 11th or 12th day of cycle and assessed 48 hours later.
Nazari et al.: Estradiol Valerate started on day 2 or 3 of menses at 6 mg/d and was 
increased to 8 mg/d if lining did not reach >7 mm. When thickness reached 7 mm, 
progesterone suppositories, 4000 mg, were started twice daily [20, 24]. In the 
pilot study, 0.5 ml of PRP was infused into the endometrium of patients 48 hours 
prior to frozen embryo transfer in conjunction with an HRT cycle. In the follow-up 
RCT, PRP infusion or mock infusion was performed on day 11 or 12 of HRT cycle, 
modified from the initial pilot study, and lining was measured using transvaginal 
ultrasonography.
Tandulwadkar et al.: Estradiol Valerate started at 6–8 mg/d concordant with 
baseline endometrial vascularity as measured by Power Doppler on day 1 of men-
ses and increased to 12 mg/d if growth was not seen. Transvaginal ultrasounds 
were performed starting on day 7/8 [21]. Day of PRP infusion was not given in the 
initial study.
Eftekhar et al.: In this study, the case group was treated with PRP and increased 
HRT, and the control group was just treated with increased HRT. For all women, 
E2V was started at 6 mg/d, then increased to 10 mg/d [22]. PRP infusion occurred 
on the 13th day of cycle and endometrial lining was measured transvaginally.
Hounyoung et al.: Patients treated within this study began E2V administration 
on the second day of menses, starting at 4-6 mg/d and followed by PRP infusion on 
cycle day 10 [23]. PRP infusion was administered via IUI catheter and repeated 2–3 
times in 3 day intervals until optimal endometrial thickness was achieved (>7 mm).
3. Sample size and selection of samples
Eight clinical trials were selected, all of which were inclusive of a total of 346 
patients that underwent HRT in conjunction with PRP infusion. Of 346 patients, 
313 underwent embryo transfer at either cleavage or blastocyst stage. The remaining 
33 patients dropped out of the studies prior to embryo transfer due to persistently 
poor endometrial development [18–25].
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3.1 Inclusion criteria
Inclusion criteria remained relatively constant through all eight studies. All 
patients had a history of thin endometrial lining, repeat implantation failure, or 
two or more canceled cycles due to poor endometrial growth. All patients were 
between the ages of 18–42 years old and all had a normal BMI of <30%; donor egg 
cycles were not included due to the potential to skew the results. All patients that 
underwent embryo transfer post-PRP infusion reached an endometrial thickness of 
>7 mm, as deemed acceptable by the performing physicians.
3.2 Exclusion criteria
All patients with hematological and immunological disorders, hormonal dis-
orders, chromosomal and genetic abnormalities and uterine abnormalities were 
excluded from the studies. All patients who did not reach optimal endometrial 
thickness post-PRP infusion were excluded from embryo transfer. Any patient of 
advanced maternal age (>42 years old) or increased BMI (>30%) was excluded 
from the studies.
4. Results and data analysis
Five patients were included in the initial pilot study by Chang et al. [18]. 
48–72 hours post PRP, all five patients reached a minimum lining of 7 mm (7.0–8.0). 
All patients underwent frozen embryo transfer, and all five patients were pregnant 
(5/5) with an ongoing pregnancy rate of 80% (4/5).
Zadehmodarres and colleagues [19] performed their study on 10 patients with 
previous canceled cycles due to thin endometrial development, four of which were 
diagnosed with Asherman’s Syndrome. All 10 patients reached adequate lining 
thickness for embryo transfer (7.0–7.5). All patients underwent frozen embryo 
transfer resulting in chemical pregnancy in 50% of patients (5/10) with an ongoing 
pregnancy rate of 40% (4/10).
The pilot study by Nazari and coworkers [20] was based upon a study group of 
20 patients suffering from RIF due to thin endometrial lining. All patients received 
a blastocyst stage transfer of one to two embryos that were graded morphologically 
normal. Chemical pregnancy was reported in 90% of patients (18/20) with an 
ongoing pregnancy rate of 80% (16/20).
Tandulwadkar et al. [21] assessed not only endometrial thickness, but endo-
metrial vascularity as well post PRP infusion as measured by serial transvaginal 
ultrasound. Of the 68 patients included in the study, 64 went on to achieve optimal 
lining thickness for frozen embryo transfer. Average mean lining thickness before 
PRP infusion was 5 mm, and 7.22 mm after PRP infusion. Of the 64 patients that 
received a frozen embryo transfer, endometrial vascularity increased in all patients. 
60.1% (39/64) reported chemical pregnancy with an ongoing pregnancy rate of 
45.3% (26/64).
A randomized control trial was performed by Eftekhar and others [22] in which 
83 women participated; 40 were allocated to the study group and received PRP 
infusion, while 43 were placed in the control group and did not receive PRP. Prior 
to PRP infusion on the 13th day of cycle, there were no significant differences 
in endometrial lining as measured between the two groups; however, after PRP 
infusion, significant differences were noted (8.80 vs. 8.04 mm). Of the 40 women 
in the study group, 7 did not receive an embryo transfer due to persistently thin 
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endometrium, whereas 10 women in the control group were excluded from frozen 
embryo transfer for the same reason. Thirty-three women in the study group and 
33 women in the control group underwent cleavage stage frozen embryo transfer. In 
the study group, chemical pregnancy was reported in 42.2% (14/33) in comparison 
to the control group, which recorded chemical pregnancy in only 24.2% (8/33) 
of patients. Ongoing pregnancy rates were 33.3% (11/33) versus 18.2% (6/33), 
respectively.
Hounyoung and colleagues [23] performed a pilot study on 24 patients with 
a history of refractory endometrium. Of the 24 patients initially included in the 
study, two patients were canceled, and two were lost to follow-up. Data was col-
lected for the remaining 20 patients, all of whom received a frozen embryo transfer 
of 2–3 day 3 cleavage stage embryos. Among the study group, a chemical pregnancy 
rate of 30% (6/20) was reported with an ongoing pregnancy rate of 20% (4/20).
After an initial pilot study, Nazari et al. [24] performed a follow-up double 
blinded randomized control trial to validate their previous findings. Sixty patients 
were selected for inclusion in the study; 30 were randomly assigned to the study 
group to receive PRP infusion, and 30 were aliquoted to the control group in which 
a sham-catheter was utilized for mock PRP infusion. In the PRP group, lining 
increased to 7.21 ± 0.18 mm respectively, and in the mock infusion group, lining 
reached 5.76 ± 0.97 mm. Of the 30 patients in the study group, all patients received a 
frozen embryo transfer in comparison to just 6 that reached optimal lining (>7 mm) 
for frozen embryo transfer in the control group. Chemical pregnancy was recorded 
in 40% (12/30) of cases in the study group, and in 6.7% (2/30) in the control group. 
Ongoing pregnancy rate was 33.3% (10/30) in the PRP group, and 3.3% (1/30) in 
the control group.
Chang and others [25] performed a follow-up randomized control trial to their 
initial pilot study as well, assigning 34 patients to the PRP infusion group and 
30 patients to the control group, which received only HRT without PRP. In the 
study group, endometrial thickness reached an average of 7.65 ± 0.22 mm versus 
6.52 ± 0.31 mm in the control group. The cycle cancelation rate was 19.0% in the 
study group, and 41.2% in the control group, which was statistically significant. All 
patients that reached optimal endometrial thickness received a frozen blastocyst 
transfer of one or two morphologically good blastocyst stage embryos. In the PRP 
group, clinical pregnancy was reported as 44.1% (15/34), and 20% (6/30) in the 
control group.
All patients within study groups that underwent embryo transfer reached opti-
mal lining thickness (>7 mm) after one or multiple rounds of PRP infusion. Patients 
that underwent PRP infusion in the study groups reached an average endometrial 
thickness of 7.36 mm with an average increase of 1.68 mm post PRP infusion. In the 
control groups presented by studies performing RCT, the control patients reached 
an average endometrial thickness of 6.77 mm with an average increase of 0.91 mm 
after HRT. Among patients within study groups, the overall chemical pregnancy 
rate was 50% (108/216) in contrast to 17.1% (16/93) following conventional HRT 
without PRP infusion.
5. Discussion
Platelet-rich plasma infusion is a novel approach to endometrium enhancement. 
This autologous therapy strives to increase endometrial thickness among patients 
with histories of canceled cycles and repeat implantation failure due to chronically 
refractive endometrium. While there is no universally agreed upon treatment for 












































Eight studies were compared for the measurement of endometrial thickness before and after PRP infusion in study groups vs. control groups. Clinical pregnancy outcomes are included following 
PRP treatment.
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endometrial lining should be at the forefront of clinical researchers within the ART 
industry. Platelet-rich plasma is easily attained, cost-effective, minimally invasive, 
rich in cytokines and growth factors, and carries very little risk of disease or infec-
tion transmission as the patient uses their own blood to attain PRP. Infusion into the 
endometrium takes place in conjunction with traditional HRT and therefore can be 
administered during the average cycle while patients are already present for serial 
ultrasounds and serum hormone level measurements.
In the eight studies discussed above, PRP infusion into the endometrium proved 
effective when administered on various days of an HRT cycle as well as in variable 
quantities. While the majority of studies reviewed were clinical applications, which 
presents a weakness in the data as there was no comparative control group, the 
randomized controlled trials that were performed offered arguably conclusive, 
supportive evidence of PRP effectiveness. All the patients that underwent PRP 
infusion experienced a significantly marked increase in endometrial thickness, 
allowing for frozen embryo transfer. In the studies that did utilize a study popula-
tion versus a control population, results among the study participants were sig-
nificantly improved with greater cycle completion. Although most studies utilized 
frozen blastocyst transfers, there were some that elected to use frozen cleavage stage 
embryo transfers, which can also be considered a limiting factor among the data. 
The studies here agreed upon 7 mm as the minimal lining thickness for embryo 
implantation success, but some physicians argue that endometrial thickness is 
a poor marker for transfer outcome. While this argument can be made and sup-
ported, as it was by Griesinger and colleagues [11], there is a wide consensus that 
endometrial thickness does play a vital role in receptivity (Table 1).
The patient populations presented in these studies, including those among the 
study group and those in the control group, were all patients that had suffered two 
or more failed previous cycles due to poor lining development. The inclusion criteria 
for these studies were consistent through all eight trials and provided an unbiased 
patient group in order to obtain reliable results. The data conclusively shows that 
endometrial thickness among patients with chronically poor endometrial develop-
ment is greatly increased with PRP infusion therapy in comparison to traditional 
HRT alone. The primary outcome of each study was satisfied by the significant 
increase in endometrial lining development with the secondary satisfaction of 
improved clinical pregnancy outcomes in the PRP group versus the control group.
Another diagnostic tool to be considered in patients with a history of subop-
timal endometrial development and repeat implantation failure is the use of the 
Endometrial Receptivity Array (ERA). The ERA is a customized array that allows 
to test for 248 different genes expressed during the endometrial cycle and works 
concordantly with a computational algorithm that identifies the receptivity status 
of an endometrial biopsy to diagnose a personalized window of implantation [28]. 
ERA is performed with a mock embryo transfer cycle. Utilizing the ERA, Ruiz-
Alonso and colleagues were able to validate conclusively that 25% of RIF patients 
had a displaced window of implantation and went on to coin the phrase “personal-
ized embryo transfer” (pET) to increase the chance of a successful pregnancy in 
women suffering from mistimed endometrial receptivity [29]. Potentially, ERA can 
be utilized in conjunction with PRP infusion to determine receptivity of the endo-
metrium in PRP patients. In the study by Tandulwadkar et al. [21], not only was 
lining thickness assessed, but endometrial vascularity was observed as well utiliz-
ing 3D Doppler ultrasound. Blood flow to the endometrium as well as the uterine 
biophysical profile can be measured via a combination between abdominal and 
transvaginal ultrasound. Greater blood flow to the uterus has been associated with 
higher implantation rates and can be seen in color utilizing Doppler ultrasound 
methods [27]. PRP infusion has the potential to increase lining development as well 
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as endometrial vascularity as proven by Tandulwadkar, and future studies should 
observe an increase in vascularity concordant with lining and uterine biophysical 
profile. Utilizing the ERA and 3D Doppler system in conjunction with PRP in future 
studies can be therefore linked to the immune, genetic, and biophysical pathways of 
the endometrium.
While the use of PRP infusion into the endometrium to increase lining 
growth and vascularity is a relatively new area of research, the initial trials show 
encouraging results. The patients that were included within these studies are 
patients who had suffered from multiple failed or canceled cycles and would not 
have received embryo transfers otherwise. In a patient population that has had 
multiple failures, PRP infusion into the endometrium provides a suitable solu-
tion that effectively allows for embryo transfer, giving these patients a chance 
at pregnancy that they otherwise would not have had utilizing traditional HRT 
alone. Although the data is still new and there is need for additional research 
and much larger randomized controlled trials, the initial use of PRP as a uni-
versal means of treating poor responders to HRT shows a promising treatment 
method for the future.
6. Conclusion
The review of the initial data presented in these eight early studies of PRP 
infusion into the endometrium in conjunction with traditional HRT reveals 
statistically significant outcomes. Patients with previous failures that did not 
reach the minimal lining thickness needed to perform embryo transfer (>7 mm) 
underwent PRP infusion into the endometrium and reached an average endome-
trial thickness of 7.36 mm in comparison to the control group, which reached an 
average of only 6.77 mm. Clinical pregnancy rates within the study group were 
also significantly higher than the control group, 50% (108/216) versus 17.1% 
(16/93), respectively. For patients that have had multiple failures and canceled 
cycles, offering an absolute solution that at minimum guarantees them an embryo 
transfer can potentially increase the success of frozen embryo transfers in clinics 
globally, while decreasing patient stress and costs, and reducing the potential for 
embryo wastage.
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